Predict your next investment

HEALTHCARE | Pharmaceuticals / Drugs

See what CB Insights has to offer

Stage

Other Investors | IPO

Market Cap

0.04B

About Vical

Vical, Inc. develops biopharmaceutical products based on our patented naked DNA gene transfer technologies for the prevention and treatment of life-threatening diseases. We currently focus our development on innovative cancer therapies designed to induce an immune response against cancer cells without causing serious side effects.

Vical Headquarter Location

San Diego, California, 92121,

United States

Latest Vical News

[2021 Edition] Immunostimulatory Adjuvants Market 2021 Research Considering Pandemic Impact On Businesses- Bayer, Adjuvance Technologies, Vical

Mar 31, 2021

[2021 Edition] Immunostimulatory Adjuvants Market 2021 Research Considering Pandemic Impact On Businesses- Bayer, Adjuvance Technologies, Vical Pune, Maharashtra, March 31 2021 (Wiredrelease) Market.Biz –:Immunostimulatory Adjuvants Market Size-Share Analysis The global Immunostimulatory Adjuvants market size is projected to gain market growth of ($ XX Mn), and it is estimated to reach $ XX Mn with a CAGR rate of XX% in the forecast period 2021-2030. Let’s grow your business with Market.Biz. The Immunostimulatory Adjuvants market report provides a detailed analysis of global market size, regional and country-level market size. The report also shows segmentation market growth, market share, competitive Landscape, sales analysis, the impact of domestic and global market players. A value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations are also examined here. Immunostimulatory Adjuvants Market segmentation Immunostimulatory Adjuvants market is split by Type and by Application. For the period 2021-2030, the growth among segments provides accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets. By Type, Immunostimulatory Adjuvants Market has been segmented into Aluminum Hydroxide Adjuvant Alum Adjuvant Liposomes, etc. By Application, Immunostimulatory Adjuvants Market has been segmented into Hospitals Medical Centers, etc. Bayer Adjuvance Technologies Vical Allergy Therapeutics BioCentury Regions and Countries Level Analysis Regional analysis is another highly comprehensive part of the research and analysis study of the global Immunostimulatory Adjuvants market presented in the report. This section sheds light on the sales growth of different regional and country-level Immunostimulatory Adjuvants markets. For the historical and forecast period 2021-2030, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Immunostimulatory Adjuvants market. The report offers an in-depth assessment of the growth and other aspects of the Immunostimulatory Adjuvants market in important countries (regions), including the United States, Canada, Mexico, Germany, France, United Kingdom, Russia, Italy, China, Japan, Korea, India, Southeast Asia, Australia, Brazil, and Saudi Arabia, etc. It also throws light on the progress of key regional Immunostimulatory Adjuvants markets such as North America, Europe, Asia-Pacific, South America, and Middle East & Africa. Competitive Landscape and Immunostimulatory Adjuvants Market Share Analysis Immunostimulatory Adjuvants competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Immunostimulatory Adjuvants sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2021-2030, this study provides the Immunostimulatory Adjuvants sales, revenue, and market share for each player covered in this report. The major players covered in Immunostimulatory Adjuvants Market are: Bayer, Adjuvance Technologies, Vical, Allergy Therapeutics, BioCentury, etc. Among other players domestic and global, Immunostimulatory Adjuvants market share data is available for global, North America, Europe, Asia-Pacific, Middle East, and Africa, and South America separately. Our analysts understand competitive strengths and provide competitive analysis for each competitor separately. The content of the study subjects includes a total of 15 chapters: Chapter 1, to describe Immunostimulatory Adjuvants product scope, market overview, market opportunities, market driving force, and market risks. Chapter 2, to profile the top manufacturers of Immunostimulatory Adjuvants, with price, sales, revenue, and global market share of Immunostimulatory Adjuvants. Chapter 3, the Immunostimulatory Adjuvants competitive situation, sales, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast. Chapter 4, the Immunostimulatory Adjuvants breakdown data are shown at the regional level, to show the sales, revenue, and growth by regions. Chapter 5, 6, 7, 8 and 9, break the sales data at the country level, with sales, revenue, and market share for key countries in the world. Chapter 10 and 11, segment the sales by type and application, with sales market share and growth rate by type, application. Chapter 12, Immunostimulatory Adjuvants market forecast, by regions, type, and application, with sales and revenue. Chapter 13, 14, and 15 describe Immunostimulatory Adjuvants sales channel, distributors, customers, research findings and conclusion, appendix, and data source. Refer to Our Related Blogs:

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Vical

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Vical is included in 1 Expert Collection, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

Vical Patents

Vical has filed 32 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/12/2014

12/8/2015

Transcription factors, Vaccines, Immune system, Vaccination, Immunology

Grant

Application Date

9/12/2014

Grant Date

12/8/2015

Title

Related Topics

Transcription factors, Vaccines, Immune system, Vaccination, Immunology

Status

Grant

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.